Department of Pediatric Cardiology and Congenital Heart Disease, German Heart Center, Munich, Germany.
Department of Pediatric Cardiology and Congenital Heart Disease, German Heart Center, Munich, Germany.
Int J Cardiol. 2018 May 1;258:31-35. doi: 10.1016/j.ijcard.2017.11.091.
To investigate the feasibility and mid-term results of percutaneous pulmonary valve implantation (PPVI) in patients with conduit free or "native" right ventricular outflow tracts (RVOT).
We identified all 18 patients with conduit free or "native" right ventricular outflow tract, who were treated with percutaneous pulmonary valve implantation (PPVI) in our institution. They were divided into two groups - these in whom the central pulmonary artery was used as an anchoring point for the preparation of the landing zone (n=10) for PPVI and these, in whom a pulmonary artery branch was used for this purpose (n=8). PPVI was performed successfully in all patients with significant immediate RVOT gradient and pulmonary regurgitation grade reduction. Four patients had insignificant paravalvular regurgitation. In one patient the valve was explanted after 4months because of bacterial endocarditis. A follow-up of 19 (4-60) months showed sustained good function of the other implanted valves. The MRI indexed right ventricular end diastolic volume significantly decreased from 108(54-174) ml/m before the procedure to 76(60-126) ml/m six months after PPVI, p=0.01.
PPVI is feasible with good mid-term results in selected patients with a "native" RVOT without a previously implanted conduit. Creating a stable landing zone with a diameter less than the largest available valve (currently 29mm) is crucial for the technical success of the procedure. Further studies and the development of new devices could widen the indications for this novel treatment.
探讨经皮肺动脉瓣植入术(PPVI)在无管道或“天然”右心室流出道(RVOT)患者中的可行性和中期结果。
我们确定了在我院接受经皮肺动脉瓣植入术(PPVI)治疗的 18 例无管道或“天然”右心室流出道患者。他们分为两组 - 10 例患者以中央肺动脉作为制备着陆区(PPVI)的锚固点,8 例患者使用肺动脉分支用于此目的。所有患者均成功进行了 PPVI,RVOT 梯度和肺动脉瓣反流程度均显著降低。4 例患者存在轻微瓣周反流。1 例患者因细菌性心内膜炎在 4 个月后进行了瓣膜取出术。19(4-60)个月的随访显示,其他植入瓣膜的功能持续良好。MRI 指数右心室舒张末期容积从术前的 108(54-174)ml/m 显著减少至 6 个月后的 76(60-126)ml/m,p=0.01。
在无先前植入管道的“天然”RVOT 患者中,PPVI 是可行的,具有良好的中期结果。创建一个直径小于可用最大瓣膜(目前为 29mm)的稳定着陆区对于该手术的技术成功至关重要。进一步的研究和新设备的开发可以扩大这种新型治疗的适应证。